Jon Faiz Kayyem, SVP, Research & Development at GenMark Diagnostics, Inc. (GNMK), sold 135 shares at $4.70 ($635) on 2017-12-04, disclosed to the SEC on 2017-12-06.
Tax-driven sale ($634) by SVP, Research & Development — typically RSU/option vesting with shares sold to cover withholding tax. Not a directional view.
Nothing distinguishes this filing.
| Filing → |
| INBX | BUY | 2026-09-08 | $568K | — | Filing → |
| INBX | BUY | 2024-11-22 | $1.5M | — | Filing → |
| INBX | BUY | 2024-06-07 | $2.0M | — | Filing → |